SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
In a new meta-analysis of PSMA PET/CT radiotracers, researchers point out the robust validation of (68Ga)Ga-PSMA-11 for prostate cancer (PCa) detection and acknowledge the unique attributes of the emerging (18F)-based radiotracers (18F)PSMA-1007 and (18F)DCFPyL.
For the meta-analysis, recently presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers reviewed data from 34 studies and a total of 5,102 patients.
The meta-analysis authors found that (68Ga)Ga-PSMA-11 (Illuccix, Telix Pharmaceuticals) provided pooled sensitivity and specificity rates of 92 percent and 90 percent, respectively, as well as an 81 percent pooled detection rate (DR).
In a new meta-analysis comparing radiotracers for PET/CT prostate cancer detection, researchers at the SNMMI conference noted robust validation for (68Ga)Ga-PSMA-11 and found the highest pooled sensitivity and detection rates for (18F)DCFPyL.
“Its rapid renal clearance improves imaging contrast and reduces nonspecific uptake, aiding systemic disease and metastasis detection,” noted lead meta-analysis author Fereshteh Yazdanpanah, M.D., MBA, a postdoctoral research fellow affiliated with the Hospital of the University of Pennsylvania, and colleagues.
However, for patients with prostate-specific antigen (PSA) levels < 0.5 ng/mL, the researchers pointed out a 16 percent higher DR for (18F)PSMA-1007 in comparison to (68Ga)Ga-PSMA-11 (84 percent vs. 68 percent).
“(The) predominantly hepatobiliary clearance (of (18F)PSMA-1007) reduces urinary excretion, improving pelvic lesion visualization, while higher SUVmax enhances nodal and micrometastatic detection,” explained Yazdanpanah and colleagues.
(Editor’s note: For additional content from the 2025 SNMMI conference, click here.)
However, the meta-analysis authors acknowledged that limitations with (18F)PSMA-1007 include the potential for false positives due to high benign bone uptake as well as higher uptake in the coeliac ganglia that can be mistaken for lymph node metastases.
The (18F)DCFPyL radiotracer (Pylarify, Lantheus) provided an overall pooled DR of 88.8 percent as well as a DR of 94.3 percent for PCa in patients with PSA levels > 0.5 ng/mL, according to the meta-analysis. The researchers noted that (18F)DCFPyL provides “significantly lower kidney uptake” than (68Ga)Ga-PSMA-11 and better specificity than (18F)PSMA-1007.
“(The) longer half-life (110 minutes) and higher positron yield (of (18F)DCFPyL) reduce image noise and enable delayed imaging protocols, making it particularly advantageous for centers without on-site gallium generators,” added Yazdanpanah and colleagues.
Reference
- Yazdanpanah F, Mhana SAA, Werner T, Alavi A, Revheim MER. Comparison of (18F)PSMA-1007, (18F)DCFPyL, and (68Ga)Ga-PSMA-11 in PET/CT imaging for prostate cancer: a systematic review and meta-analysis. Presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference June 21-24, 2025, New Orleans, La. Available at: https://www.xcdsystem.com/snmmi/program/B95p18u/index.cfm?pgid=2402&sid=47321 .
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Recent Videos
Related Content
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025Article
For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025Article
In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025Article
In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Article
Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Article
Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
